RVNC vs. ARQT, AMPH, IMCR, AAPG, KNSA, DYN, GPCR, ARDX, INDV, and NRIX
Should you be buying Revance Therapeutics stock or one of its competitors? The main competitors of Revance Therapeutics include Arcutis Biotherapeutics (ARQT), Amphastar Pharmaceuticals (AMPH), Immunocore (IMCR), Ascentage Pharma Group International (AAPG), Kiniksa Pharmaceuticals (KNSA), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Ardelyx (ARDX), Indivior (INDV), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.
Revance Therapeutics vs.
Revance Therapeutics (NASDAQ:RVNC) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
Arcutis Biotherapeutics has lower revenue, but higher earnings than Revance Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.
97.7% of Revance Therapeutics shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Revance Therapeutics presently has a consensus price target of $8.39, indicating a potential upside of 129.75%. Arcutis Biotherapeutics has a consensus price target of $16.60, indicating a potential upside of 27.39%. Given Revance Therapeutics' higher probable upside, research analysts clearly believe Revance Therapeutics is more favorable than Arcutis Biotherapeutics.
In the previous week, Revance Therapeutics had 11 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 14 mentions for Revance Therapeutics and 3 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.25 beat Revance Therapeutics' score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Revance Therapeutics has a net margin of -74.67% compared to Arcutis Biotherapeutics' net margin of -140.97%. Revance Therapeutics' return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.
Revance Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500.
Revance Therapeutics received 338 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 65.63% of users gave Arcutis Biotherapeutics an outperform vote while only 60.57% of users gave Revance Therapeutics an outperform vote.
Summary
Revance Therapeutics and Arcutis Biotherapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Revance Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revance Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RVNC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free RVNC Stock Alerts